MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine to evaluate several intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Key trial goals have been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though among the exploratory goals https://napoleone443seq7.wikikali.com/user